Agilent Announces Deals in South Korea for Clinical Assay Development, Neurometabolomic Research | GenomeWeb

NEW YORK (GenomeWeb News) – Agilent Technologies separately announced on Thursday a collaboration with Samsung Medical Center and the creation of a new center for neurometabolomics in South Korea.

Under the terms of the deal with Samsung, the Department of Laboratory Medicine & Genetics Research in Seoul, South Korea — part of the Center for Future Medicine at Samsung Medical Center — will use bio-analytical instruments from Agilent for the analysis of clinical samples and to develop novel clinical assays.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.